Keyphrases
Phase II Study
100%
Chronic Lymphocytic Leukemia
100%
Richter Transformation
100%
Ibrutinib
100%
Diffuse Large B Cell
100%
Nivolumab
100%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
BTK Inhibitor
25%
Therapeutic Potential
12%
Median Overall Survival
12%
Potential Therapeutics
12%
Complete Remission
12%
Hepatic Function
12%
Duration of Response
12%
Overall Response Rate
12%
Prior Treatment
12%
Renal Function
12%
Phase II Clinical Trial
12%
Programmed Death-ligand 1 (PD-L1)
12%
Patients Included
12%
Rare Complication
12%
Tumor Cell Death
12%
Limited Treatment Options
12%
Investigator-initiated
12%
Anti-PD-1 Antibody
12%
Checkpoint Inhibition
12%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
B Cell
100%
Richter's Transformation
100%
Ibrutinib
100%
Nivolumab
100%
Diffuse Large B-Cell Lymphoma
25%
Clinical Trial
12%
Overall Survival
12%
Tumor Cell
12%
Liver Function
12%
Upregulation
12%
Kidney Function
12%
Drive
12%
Blocking Antibody
12%
Cell Killing
12%
Programmed Death-Ligand 1
12%
Immunology and Microbiology
B Cell
100%
Nivolumab
100%
Tumor Cell
16%
Overall Survival
16%
Upregulation
16%
Liver Function
16%
Kidney Function
16%
Programmed Death-Ligand 1
16%
Blocking Antibody
16%
Cell Killing
16%